• <nav id="08sis"></nav>
  • <menu id="08sis"><strong id="08sis"></strong></menu>
  • <menu id="08sis"><nav id="08sis"></nav></menu>
  • <dd id="08sis"></dd>
  • <menu id="08sis"></menu>
  •  
     
    Company News 
    Corporate?Activities 
    Industry?News 
    Contact: Mr Gerry
    Tel: 86-21-61900721
                      61900733
    Fax: 86-21-61900735
    Mobile: 86-13636696795
    E-mail: sales@run-biotech.com
    Website: www.cnhbian.com

    FDA Approves New Multiple Sclerosis Drug
    Shanghai Run-Biotech Co.,Ltd.   2013-04-11 23:58:45 Author:By Robert Preidt HealthDay Reporter Source:WebMD News from HealthDay Font size:[Large][Middle][Small]

    THURSDAY, March 28 (HealthDay News) -- A new drug called Tecfidera has been approved to treat adults with relapsing forms of multiple sclerosis, the U.S. Food and Drug Administration said Wednesday.

    The approval is based on the results of two clinical trials showing that patients who took Tecfidera (dimethyl fumarate) capsules had fewer MS relapses than those who took an inactive placebo. One of the trials also showed that a worsening of MS-related disability occurred less often in patients who took the drug than in those who took the placebo.

    "Tecfidera will be a welcome addition to the growing list of agents that alter the course of multiple sclerosis," said one expert, Dr. Fred Lublin, director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York City.

    "Based on the clinical trial data available, this new agent has very impressive efficacy data and a good safety profile," he added.

    The FDA said that Tecfidera may lower levels of white blood cells, which help protect the body from infection. Lower levels of white blood cells may increase the risk of infection, but no significant increase in infections occurred in patients taking the drug.

    Before starting treatment with Tecfidera, and each year after, doctors should check patients' white blood cell counts, the FDA advised.

    Flushing (warmth and redness), nausea, vomiting and diarrhea were the most common side effects in patients taking the drug, especially at the start of treatment with Tecfidera, which is made by Biogen Idec in Massachusetts.

    "No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients," Dr. Russell Katz, director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

    "Multiple sclerosis can impair movement, sensation and thinking, and have a profound impact on a person's quality of life," he added.

    MS is an autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body, resulting in problems such as muscle weakness and difficulty with coordination and balance.

    For most MS patients, periods of worsening disability (relapses) are initially followed by recovery periods (remissions). Over time, these recovery periods may be incomplete, resulting in a progressive increase in disability.

     

    About us Projects Services News Client Support
    Our Team
    R & D Capabilities
    Enterprise Culture
     

    Pharmaceutical Discovery
    bio-pharmaceuticals
    Biological Reagents
    Analysis & Separation
    Natural Healthcare
    Standard Sample
    Process Development
    Preclinical Research

     
    Company News
    Corporate Activities
    Industry News
     
    Download
    Login
    Feedback
    Contact us
    Job

    Shanghai Run-Biotech Co.,Ltd. Copyright ? 2013

    module not exist 久碰香蕉线视频在线观看视频_日韩10000免费拍拍拍_中国一级牲交作爱片免费观看_四库影院永久国产精品 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>